<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693654</url>
  </required_header>
  <id_info>
    <org_study_id>00000656</org_study_id>
    <secondary_id>31648</secondary_id>
    <nct_id>NCT00693654</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients</brief_title>
  <official_title>A Controlled Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Pruritus in Adult Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the efficacy of SARNA Sensitive Lotion in
      the treatment of uremic pruritus in adult hemodialysis patients in a double-blind Controlled
      comparative trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 4-week, randomized, double-blind, controlled study. Fourteen subjects received
      treatment lotion (1% pramoxine HCl) and the remaining 14 received a bland emollient (Cetaphil
      lotion). A target lesion limited to one anatomic site, excluding face and genitals, was
      selected at baseline. Each subject was instructed to apply lotion twice daily to all affected
      areas of pruritus for four weeks. The use of any other topical or systemic medication to
      treat uremic pruritus was not permitted while participating in the study. Subjects were
      clinically evaluated for erythema, xerosis, lichenification and overall severity at baseline,
      week 1, and week 4 (end of study)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>Disease severity assessed at baseline and 4 weeks, week 4 reported</time_frame>
    <description>Investigator's Global Assessment Disease Severity is based on the following scale:
0 = completely clear: except for possible residual hyper pigmentation
= almost clear: very significant clearance (about 90%)
= Marked improvement: significant improvement (about 75%)
= Moderate improvement: intermediate between slight and marked; representing about 50% improvements
= Slight improvement: some improvement (about 25%); however, significant disease remaining
= No change (moderate to severe disease)
= Worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS of Pruritus</measure>
    <time_frame>Assessed at baseline and 4 weeks, week 4 reported</time_frame>
    <description>Subject's self assessment of itching based on a 100 mm visual analog scale with 0 being no itching and 10 being most severe itching</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pruritis</condition>
  <arm_group>
    <arm_group_label>Sarna Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% pramoxine Sarna lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cetaphil lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Cetaphil lotion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarna</intervention_name>
    <description>Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&amp;) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide</description>
    <arm_group_label>Sarna Lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetaphil</intervention_name>
    <description>Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid</description>
    <arm_group_label>Placebo Cetaphil lotion</arm_group_label>
    <other_name>Cetaphil Lotion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years of age to 70 years of age.

          -  A diagnosis of moderate to severe pruritus.

          -  At least 3 episodes of itch over a period of 2 weeks, each lasting for 2 minutes or
             more.

          -  Symptoms of itch in regular pattern over 6 months.

          -  Itch Visual analog scale (VAS) of 3cm or more out of 10 cm.

          -  All subjects will be end stage renal failure patients undergoing hemodialysis for at
             least 3 months, who have substantial pruritus for more than 6 months. Substantial
             pruritus is defined as persistent pruritus impairing sleep or daytime activity.

          -  Ability and willingness to follow all study procedures, attend all scheduled visits,
             and successfully complete the study

          -  The ability to understand and sign a written informed consent form, which must be
             obtained prior to treatment.

        Exclusion Criteria:

          -  Presence of infection (as defined by the investigator) on the area to be treated.

          -  Subjects with history of pruritus predating renal failure and subjects with skin
             disease unrelated to uremia, such as atopic dermatitis, will be excluded.

          -  Use of systemic medications for treatment of pruritus including corticosteroids within
             the past 4 weeks and during the study.

          -  Use of topical medications for treatment of pruritus, including corticosteroids,
             within the past week.

          -  Pregnant women, women who are breast feeding, or women of child bearing potential who
             are not practicing an acceptable method of birth control (abstinence, birth control
             pill/patch, barrier with spermicidal jelly, IUD, etc.), as determined by the
             investigator. Acceptable contraception must be used during the entire study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Fleischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Dermatology</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <results_first_submitted>November 12, 2010</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uremic Pruritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramoxine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 11/6/06 to 11/27/06 from the Salem Kidney Center in Winston Salem, NC.</recruitment_details>
      <pre_assignment_details>Subjects were randomized so that half received Sarna lotion to be applied twice daily to all areas of pruritus, the other half applied placebo lotion twice daily to areas of pruritus.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pramoxine Lotion</title>
          <description>Active Medicated Pramoxine Lotion (Sarna) applied topically twice daily to areas of pruritus</description>
        </group>
        <group group_id="P2">
          <title>Placebo Cetaphil Lotion</title>
          <description>Placebo lotion (Cetaphil) applied twice daily to areas of pruritus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Active Medicated Lotion (Sarna)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo lotion (Cetaphil)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="13.6"/>
                    <measurement group_id="B2" value="58.0" spread="7.54"/>
                    <measurement group_id="B3" value="53.5" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator Global Assessment</title>
        <description>Investigator’s Global Assessment Disease Severity is based on the following scale:
0 = completely clear: except for possible residual hyper pigmentation
= almost clear: very significant clearance (about 90%)
= Marked improvement: significant improvement (about 75%)
= Moderate improvement: intermediate between slight and marked; representing about 50% improvements
= Slight improvement: some improvement (about 25%); however, significant disease remaining
= No change (moderate to severe disease)
= Worse</description>
        <time_frame>Disease severity assessed at baseline and 4 weeks, week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Active Medicated Pramoxine Lotion (Sarna)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo lotion (Cetaphil)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment</title>
          <description>Investigator’s Global Assessment Disease Severity is based on the following scale:
0 = completely clear: except for possible residual hyper pigmentation
= almost clear: very significant clearance (about 90%)
= Marked improvement: significant improvement (about 75%)
= Moderate improvement: intermediate between slight and marked; representing about 50% improvements
= Slight improvement: some improvement (about 25%); however, significant disease remaining
= No change (moderate to severe disease)
= Worse</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="0.37"/>
                    <measurement group_id="O2" value="2.32" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS of Pruritus</title>
        <description>Subject's self assessment of itching based on a 100 mm visual analog scale with 0 being no itching and 10 being most severe itching</description>
        <time_frame>Assessed at baseline and 4 weeks, week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Active Medicated Lotion (Sarna)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo lotion (Cetaphil)</description>
          </group>
        </group_list>
        <measure>
          <title>VAS of Pruritus</title>
          <description>Subject's self assessment of itching based on a 100 mm visual analog scale with 0 being no itching and 10 being most severe itching</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.12"/>
                    <measurement group_id="O2" value="2.82" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Active Medicated Lotion (Sarna)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo lotion (Cetaphil)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Fleischer, Jr., MD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-7753</phone>
      <email>afleisch@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

